References
- B. Stewart and P. Kleihues, World Cancer Report, IARC Press, Lyon 2003.
- National Cancer Institute, Methods for Treatment and Their Side Effectshttp://www.nci.nih.gov/cancertopics/wyntk/overview/page15
- T. W. Fischer, M. A. Zmijewski, B. Zbytek, T. W. Sweatman, R. M. Slominski, J. Wortsman and A. Slominski, Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines, Int. J. Oncol. 29 (2006) 665-672.
- H. Brenner, Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis, Lancet 360 (2001) 1131-1135; DOI: 10.1054/bjoc.2001.1905.
- J. L. Gajewski and R. E. Champlin, Blood Stem Cell and Marrow Transplantation, in Cancer Treatment (Ed. C. M. Haskell and J. S. Berek), W. B. Saunders, Philadelphia 2001, pp. 276-295.
- S. Bucurescu, Introduction to Pharmaceutical Medicine, RG Fischer Verlag, Frankfurt am Main 2008, pp. 118-122.
- N. dePace, Sulla scomparsa di un enorme cancro vegetante del collo dell'utero senza cura chirurgica, Ginecologia 9 (1912) 82-89.
- E. Kelly and S. J. Russel, History of oncolytic viruses: genesis to genetic engineering, Mol. Ther. 15 (2007) 651-659; DOI: 10.1038/sj.mt.6300108.
- T-C. Liu and D. Kirn, Gene therapy progress and prospects cancer: oncolytic viruses, Gene Ther. 15 (2008) 877-884; DOI: 10.1038/gt.2008.72.
- K. Garber, China approves world's first oncolytic virus therapy for cancer treatment, J. Natl. Cancer I. 98 (2006) 298-300; DOI: 10.1093/jnci/djj111.
- S. Meerani and Y. Yao, Oncolytic viruses in cancer therapy, Eur. J. Sci. Res. 40 (2010) 156-171.
- Z. S. Guo, S. H. Thorne and D. L. Bartlett, Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses, Biochim. Biophys. Acta 1785 (2008) 217-231; DOI: 10.1016/j.bbcam.2008.02.001.
- S. Naik and S. J. Russel, Engineering oncolytic viruses to exploit tumor specific defects in innate immune signalling pathways, Expert Opin. Biol Th. 9 (2009) 1163-1176; DOI: 10.1517/14712590903170653.
- R. Diasio and A. F. LoBuglio, Immunomodulators: Immunosuppressive Agents and Immunostimulants, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Ed. J. G. Hardman, A. Goodman Gilman and L. E. Limbird), McGraw-Hill, New York, 2006, pp. 1291-1308.
- D. J. McGeoch, J. A. Dolan, S. Donald and F. J. Rixon, Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1, J. Mol. Biol. 181 (1985) 1-13; DOI: 10.1016/0022-2836(85)90320-1.
- H. M. Friedman, Immune evasion by herpes simplex virus type 1, strategies for virus survival, Trans. Am. Clin. Climatol Assoc. 114 (2008) 103-112.
- D. Westmoreland and J. F. Watkins, The IgG receptor induced by herpes simplex virus: studies using radioiodinated IgG, J. Gen. Virol. 24 (1974) 167-178; DOI: 10.1099/0022-1317-24-1-167.
- J. P. G. Sissons, Herpes Viruses (Excluding Epstein-Barr Virus), in Oxford Textbook of Medicine (Eds. D. A. Warell, T. M. Cox, J. D. Firth and E. J. Benz), Oxford University Press, New York 2003, pp. 327-341.
- J. Sambrook and D. Russel D, The Condensed Protocols from Molecular Cloning: a Laboratory Manual, CSHL Press, Cold Spring Harbor 2006.
- J. Vieira and J. Messing, The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers, Gene 19 (1982) 259-268; DOI 10.1016/0378-1119(82)90015-4.
- F. Baneyx, Recombinant protein expression in Escherichia coli, Curr. Opin. Biotechnol. 10 (1999) 411-421; DOI: 10.1016/50958-1669(99)00003-8.
- J. Weiss, Handbook of Ion Chromatography, Wiley-VCH, Weinheim 2004, pp. 279-349.
- J. F. Watkins, Adsorption of sensitized sheep erythrocytes to HeLa cells infected with herpes simplex virus, Nature 202 (1964) 1364-1365; DOI: 10.1038/2021364a0.
- T. Van Dyke and T. Jacks, Cancer modeling in the modern era: progress and challenges, Cell 108 (2002) 135-144; DOI: 10.1016/S0092-8674(02)00621-9.
- D. Cervantes-Garcia, R. Ortiz-Lopez, N. Mayek-Perez and A. Rojas-Martinez, Oncolytic virotherapy, Ann. Hepatol. 7 (2008) 34-45.
- N. Ting, Dose Finding in Drug Development, Springer, New York 2006, pp. 304-310.
- R. C. Rowe, P. J. Sheskey and M. E Quinn, Handbook of Pharmaceutical Excipients, Pharmaceutical Press, Chicago 2009, pp. 69-301.
- International Conference on Harmonisation, Harmonised Tripartite Guideline, Timing of Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals, ICH, Geneve 1998; http://www.ema.europa.eu/ema/index.jsp?cure=pages/regulation/general/general_content_000430.jsp&murl=menus/regulations/regulation.jsp&mid=WC0b01ac058002992&jsenabled=true
- International Conference on Harmonisation Harmonised Tripartite Guideline, The Principles of Good Clinical Practice, ICH, Geneve 1996; http://www.ich.org/LOB/media/MEDIA482.pdf